Scholars Central

Short communicationPublished 5 Aug 2016

Lung cancer drug resistance and DNA damage signaling

Authors: Peilin Zhang

Clinical Practice

Volume 2 · Issue 3 · Pages 381

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The most challenging problem in cancer therapy is tumor resistance to treatment modalities, such as chemo- and radiation therapy. There are two types of resistances to DNA damage-inducing agents; first, naturally occurring resistance; and second, therapy-induced resistance. Advances in understanding the molecular mechanism that regulates the DNA damage signaling pathway makes it possible to better define the key regulatory targets involving the development of tumor resistance. In this brief review, we summarize the recent advances in DNA damage signaling, and discuss the potential targets for drug developments and better design of clinical trials for cancer patients, especially lung cancer patients.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Peilin Zhang”